Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR trial: standard versus modified tyrosine kinase inhibitor strategy in renal cancer
ISRCTN06473203Phase 3Completed
- Sponsor
- University of Leeds
- Start
- Oct 2011
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of sunitinib and pazopanib in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by University of Leeds. Primary endpoints: Recruitment rate per month, Time to strategy failure and 2 more. Started Oct 2011; status: completed.
02
Drugs
sunitinibpazopanib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ISRCTN06473203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN06473203.